Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. (10th October 2018)

• Record Type: Journal Article
• Authors: Harvey, R. Donald; Aransay, Noemi Reguart; Isambert, Nicolas; Lee, Jong‐Seok; Arkenau, Tobias; Vansteenkiste, Johan; Dickinson, Paul A.; Bui, Khanh; Weilert, Doris; So, Karen; Thomas, Karen; Vishwanathan, Karthick
• Is Part Of: British journal of clinical pharmacology. Volume 84:Number 12(2018)
• Page Start: 2877
• Page End: 2888
• Publication Date: 2018-10-10
• Subjects: CYP3A -- BCRP -- NSCLC -- osimertinib; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.13753
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aim: We report on two Phase 1, open‐label, single‐arm studies assessing the effect of osimertinib on simvastatin (CYP3A substrate) and rosuvastatin (breast cancer resistance protein substrate [BCRP] substrate) exposure in patients with advanced epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer who have progressed after treatment with an EGFR tyrosine kinase inhibitor, to determine, upon coadministration, whether osimertinib could affect the exposure of these agents. Methods: Fifty‐two patients in the CYP3A study (pharmacokinetic [PK] analysis, n = 49), and 44 patients in the BCRP study were dosed (PK analysis, n = 44). In the CYP3A study, patients received single doses of simvastatin 40 mg on Days 1 and 31, and osimertinib 80 mg once daily on Days 3–32. In the BCRP study, single doses of rosuvastatin 20 mg were given on Days 1 and 32, and osimertinib 80 mg once daily on Days 4–34. Results: Geometric least squares mean (GLSM) ratios (90% confidence intervals) of simvastatin plus osimertinib for area under the plasma concentration–time curves from zero to infinity (AUC) were 91% (77–108): entirely contained within the predefined no relevant effect limits, and C max of 77% (63, 94) which was not contained within the limits. GLSM ratios of rosuvastatin plus osimertinib for AUC were 135% (115–157) and C max were 172 (146, 203): outside the no relevant effect limits. Conclusions: Osimertinib is unlikely to have any clinically relevant interaction with CYP3A substrates and has a weak inhibitory effect on BCRP. No new safety concerns were identified in either study.